Chinese Medicine in Management of Chronic Disease Endometriosis

article OA: closed CC0 ⤵ 5 in-corpus citations
AI-generated summary by claude@2026-06+body, 2026-06-07

Chinese medicine can inhibit endometriosis recurrence, improve quality of life, and increase pregnancy rates with few adverse reactions, making it a viable option for long-term management.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text

This paper discusses Chinese medicine (CM) as a long-term management strategy for chronic endometriosis, drawing on the authors’ prior studies and related literature on postoperative recurrence, quality of life, time to conception, and pregnancy rates. The paper’s central claims are that CM can inhibit postoperative recurrence, improve quality of life, shorten time to conception, and increase pregnancy rates while producing few adverse reactions and high safety. A key caveat is that the evidence base described is primarily based on the authors’ previous work and cited studies, without providing new primary data, detailed trial methods, or an explicit limitations section in the text provided. This paper is centrally about endometriosis — it promotes Chinese medicine for chronic long-term management, particularly targeting postoperative recurrence and fertility-related outcomes.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis (EM), a refractory, highly recurrent and life-threatening chronic disease, requires long-term management and long-term drug treatment. Our previous studies showed that Chinese medicine (CM) can inhibit the postoperative recurrence of EM, improve quality of life, shorten the time to conception and increase pregnancy rates. CM produces few adverse reactions with high safety. These characteristics might be associated with the mechanism of CM's inhibition of recurrence. Therefore, we believe that CM may represent a good choice for long-term drug treatment and is worthy of clinical application.
Full text 4,621 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Endometriosis (EM), a refractory, highly recurrent and life-threatening chronic disease, requires long-term management and long-term drug treatment. Our previous studies showed that Chinese medicine (CM) can inhibit the postoperative recurrence of EM, improve quality of life, shorten the time to conception and increase pregnancy rates. CM produces few adverse reactions with high safety. These characteristics might be associated with the mechanism of CM’s inhibition of recurrence. Therefore, we believe that CM may represent a good choice for long-term drug treatment and is worthy of clinical application. Similar content being viewed by others

References

Leng JH, Dai Y. New ideas for the treatment of endometriosis. Chin J Obstet Gynecol (Chin) 2017;52:433–435. Lang JH. The study and hypothesis of endometriosis. Chin J Obstet Gynecol (Chin) 2003;38:478–480. Liu SJ, Zhang W, Zhang XH, Cai GQ, Zhou W, et al. The implementation of de-escalation therapy for inhibition and protection of ovarian function in lifetime management of endometriosis. Med Phil (Chin) 2015;36:22–25. Rothenberg RB, Koplan JP. Chronic disease in the 1990s. Annu Rev Public Health 1990;11:267–296. Lu M, Cui YM, Bai WP. Pharmaceutical care model on chronic disease management. Chin J New Drugs (Chin) 2014;23:244–246. Li TT, Sun WW, Zhao RH. Clinical observation on the treatment with Huoxue Xiaoyi Fang for ovarian endometriosis with syndrome of qi stagnation and blood stasis. Modern J Integr Tradit West Med (Chin) 2018;27:484–487, 549. Cui YY, Sun WW, Zhao RH. Systematic review of Chinese herbal medicine for controlling recurrence of endometriosis after operation. J Shandong Univ Tradit Chin Med (Chin) 2014;38:529–533. Zhao RH, Hao ZP, Zhang Y, Lian FM, Sun WW, Liu Y, et al. Controlling the recurrence of pelvic endometriosis after a conservative operation: comparison between Chinese herbal medicine and Western medicine. Chin J Integr Med 2013;19:820–825. Zhao RH, Liu Y, Tan Y, Hao ZP, Meng QW, Wang R, et al. Chinese medicine improves postoperative quality of life in endometriosis patients: a randomized controlled trial. Chin J Integr Med 2013;19:15–21. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril 2014;101:927–935. Liang JH, ed. A Meta of clinical guide collected by Chinese Journal of Obstetrics and Gynecology (2015 ed). Beijing: People’s Medical Publishing House;2015:311. Kvaskof M, Mu F, Tery K L, Harris HR, Poole EM, Farland L, et al. Endometriosis: a high-risk population for major chronic diseases. Hum Reprod Update 2015;21:500–516. Zhang W, Chen LF, Liu SJ, Yang H, Xin XY. Practice the basic principle of "patient benefit": a discussion from the clinical management of endometriosis involving the urinary and reproductive system. Med Phil 2014;35:81–83. Kuznetsov L, Dworzynski K, Davies M. Diagnosis and management of endometriosis: summary of NICE guidance. BMJ 2017;358:j3935 Li MH, Leng JH, Li CL, Shi JH, Jia SZ, Lang JH. Study on the expression of tPA and PAI-1 in endometriosis peritoneum treated by GnRH-a. Prog Obstet Gynecol 2012;21:20–23. Wu XY, Wan ZQ, Zhang YZ. Zoladex combined with Laparoscopic surgery to treat 38 cases of endometriosis. Zhejiang J Prev Med (Chin) 2006;18:45–47. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update 2009;15:441–461. Jee BC, Lee JY, Suh CS. Impact of GnRH agonist treatment on recurrence of ovarian endometriomas after conservative laparoscopic surgery. Fertil Steril 2009;91:40–45. Yang LB. Long-term management of endometriosis. Modern Med Health 2017;1:156–158. Zhao RH, Yang YH, Li M, Xu C, Xia WY. Influences of Huoxue Xiaoyi Fang on ICAM-1, MMP-9 and VEGF in rats with endometriosis. J Beijing Univ Chin Med (Chin) 2012;35:826–830. Sun WW, Yang YH, Hao ZP, Li M, Zheng Y. Effect of Danchi Decoction on serum interleukin of endometriosis. Chin J Inf Tradit Chin Med (Chin) 2014;21:14–17. Yang YH, Zhao RH, Hao ZP, Li L, Xu C. Effects of Danchi Decoction on P450arom, survivin of eutopic endometrium of patients with endometriosis after conservative surgery. Afr J Tradit Complement Altern Med 2015;12:65–71. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Zhao, Rh., Sun, Ww., Liu, Y. et al. Chinese Medicine in Management of Chronic Disease Endometriosis. Chin. J. Integr. Med. 26, 88–91 (2020). https://doi.org/10.1007/s11655-018-2937-3 Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s11655-018-2937-3

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometriosis Medicine, Chinese Traditional Chronic Disease Combined Modality Therapy Endometriosis Endometriosis Female Humans Quality of Life Recurrence

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (14)

Cited by (5)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:01.354358+00:00
unpaywall
last seen: 2026-07-27T06:55:32.580041+00:00
License: CC0 · commercial use OK